SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002,110. This patent, which allows exclusively through 2018, covers compositions of fusion proteins comprised of a human papillomavirus (HPV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins. This decision dismisses an appeal announced on January 30, 2006, and upholds the EPO Opposition Division's favorable decision of October 2005.
"We are very pleased with the Technical Board's decision to once again uphold this important European patent," said Gregory M. McKee, president and chief executive officer of Nventa. "This favorable ruling reaffirms the strength of our intellectual property portfolio and reinforces an important composition-of-matter patent covering our lead product candidate, HspE7, and other future therapeutics for HPV-related diseases and cancer."
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa, please visit http://www.nventacorp.com.
The company's lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.
CONTACT: Donna Slade, Director, Investor Relations of Nventa
Biopharmaceuticals Corporation, +1-858-202-4945, email@example.com; or
media, Tim Brons of Vida Communication, +1-415-675-7402,
firstname.lastname@example.org; or Michael Moore of The Equicom Group,
+1-416-815-0700, ext. 241, email@example.com, for Nventa
Web site: http://www.nventacorp.com/